Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PyramIDH: Ivosidenib vs Azacitidine in IDH1-mutant HMA-naive MDS
2023-510155-37-00Phase 3Authorised
- Sponsor
- Servier
- Start
- Dec 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, open-label trial in myelodysplastic syndrome (MDS) comparing Ivosidenib monotherapy with Azacitidine (Vidaza) monotherapy (2 arms). Primary endpoint: Complete remission (CR) + Partial remission (PR) by 4 months (IWG 2006). Planned start Dec 2024; status: authorised.
02
Drugs
ivosidenibazacitidine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2023-510155-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510155-37-00.